Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03472274
Title Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fundacion CRIS de Investigacion para Vencer el Cancer
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Cisplatin + Doxorubicin + Methotrexate + Vinblastine

Cisplatin + Gemcitabine

Cisplatin + Gemcitabine + Paclitaxel

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
ICO Badalona Recruiting Badalona Spain Details
Hospital Clinic Recruiting Barcelona Spain Details
Hospital de la Santa Creu i Sant Pau Recruiting Barcelona Spain Details
ICO L'Hospitalet Recruiting L'Hospitalet De Llobregat Spain Details
Hospital 12 de Octubre Recruiting Madrid Spain Details
Hospital Clinico San Carlos Recruiting Madrid Spain Details
Hospital Ramon y Cajal Recruiting Madrid Spain Details
Hospital Universitario La Paz Recruiting Madrid Spain Details
MD Anderson Cancer Center Recruiting Madrid Spain Details
Hospital Marqués de Valdecilla Recruiting Santander Spain Details
Instituto Valenciano de Oncología Recruiting Valencia Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field